Declining prices for generic drugs in the U.S. are hurting corporate earnings at drugmakers, medical distributors and pharmacy chains, rattling stocks and imperiling a major acquisition of one drugstore company.
Prices have been driven down by consolidation among buyers, faster approval of competing pills by U.S. regulators and deals between manufacturers to further wring out costs. In June and July, generic drugs were 7 percent to 8 percent cheaper than a year before, according to Evercore ISI.
The next major generic-drug manufacturers to report are Mylan NV and Endo International Plc, on Wednesday, and investors have been watching them closely. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.